Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

(2012) J. Aimiuwu et al.   BLOOD

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

(2012) W. Blum et al.   BLOOD

Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia

(2011) D. Sampath et al.   BLOOD

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

(2011) M. Kalac et al.   BLOOD

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

(2011) K H Metzeler et al.   LEUKEMIA

Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma

(2011) Bevin Zimmerman et al.   LEUKEMIA RESEARCH

Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA

(2010) Hui Yang et al.   AMERICAN JOURNAL OF HEMATOLOGY

The prognostic and functional role of microRNAs in acute myeloid leukemia

(2010) G. Marcucci et al.   BLOOD

MicroRNAs expression signatures are associated with lineage and survival in acute leukemias

(2010) Yungui Wang et al.   BLOOD CELLS MOLECULES AND DISEASES

Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia

(2010) Shujun Liu et al.   CANCER CELL

The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells

(2010) Shuhong Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival

(2010) Lara Tickenbrock et al.   LEUKEMIA RESEARCH

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

(2010) David M. Lucas et al.   PLoS One

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

(2009) R. Garzon et al.   BLOOD

MicroRNA 29b functions in acute myeloid leukemia

(2009) R. Garzon et al.   BLOOD

Treatment of acute myeloid leukemia

(2009) E. H. Estey   HAEMATOLOGICA

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias

(2008) Giuseppe Leone et al.   CURRENT MEDICINAL CHEMISTRY

Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells

(2008) Q. Zhou et al.   MOLECULAR CANCER RESEARCH